The development of novel PET imaging agents that selectively bind specific dementia-related targets can contribute significantly to accurate, differential and early diagnosis of dementia causing diseases and support the development of therapeutic agents. Consequently, in recent years there has been a growing body of literature describing the development and evaluation of potential new promising PET tracers for dementia. This review article provides a comprehensive overview of novel dementia PET probes under development, classified by their target, and pinpoints their preclinical evaluation pathway, typically involving in silico, in vitro and ex/in vivo evaluation. Specific target-associated challenges and pitfalls, requiring extensive and well-designed preclinical experimental evaluation assays to enable successful clinical translation and avoid shortcomings observed for previously developed ‘well-established’ dementia PET tracers are highlighted in this review.
CITATION STYLE
Cools, R., Kerkhofs, K., Leitao, R. C. F., & Bormans, G. (2023, September 1). Preclinical Evaluation of Novel PET Probes for Dementia. Seminars in Nuclear Medicine. W.B. Saunders. https://doi.org/10.1053/j.semnuclmed.2023.03.004
Mendeley helps you to discover research relevant for your work.